We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Everolimusis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Everolimus studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality randomised trials published 2008–2025 with a typical study size of 410 participants.
Based on 7 studies · 5 RCTs · 1,616 total participants
Confidence
HighBy outcome
Everolimus has an evidence score of 4.2/10 — emerging evidence based on 7 indexed studies, including 1 meta-analysis. A rapamycin analog (rapalog, RAD001) approved as an oncology drug (Afinitor) and transplant immunosuppressant (Zortress). It is the mTOR inhibitor with the cleanest human geroscience signal: randomized trials in older adults showed it improved vaccine response and reduced infections — an immune-aging benefit, NOT demonstrated lifespan extension. A prescription immunosuppressant, not a supplement, and its later phase-3 respiratory-illness sibling trial missed its endpoint. Representative study: PMID 35861940.
The commonly studied dose of Everolimus is No validated longevity dose. Geroscience trials used low intermittent dosing (e.g. ~0.5 mg/day or ~5 mg/week of RAD001) — unproven and not an approved regimen. Approved oncology dosing is 10 mg/day (Afinitor) and transplant dosing is trough-titrated (Zortress); both are far higher than any longevity protocol.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Rapamycin
Mostly mechanism / observationalAn FDA-approved mTOR-inhibitor immunosuppressant (sirolimus, Rapamune) taken off-label for longevity. It is the most robustly lifespan-extending compound in animal studies across species, but human longevity benefit is unproven — the human data are short-term immune/biomarker trials, and it carries real immunosuppression risks. A prescription drug, not a supplement.
CoQ10
Last reviewed June 2026 · evidence from 7 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Everolimus (Afinitor / Zortress) — mTOR inhibitor (rapalog)
A rapamycin analog (rapalog, RAD001) approved as an oncology drug (Afinitor) and transplant immunosuppressant (Zortress). It is the mTOR inhibitor with the cleanest human geroscience signal: randomized trials in older adults showed it improved vaccine response and reduced infections — an immune-aging benefit, NOT demonstrated lifespan extension. A prescription immunosuppressant, not a supplement, and its later phase-3 respiratory-illness sibling trial missed its endpoint.
Everolimus is the mTOR inhibitor with the most directly relevant human geroscience data — randomized trials in older adults showing improved vaccine response and reduced infections (an immune-aging signal) — but no human trial shows it extends lifespan or healthspan, the program's larger confirmatory RTB101 phase-3 trial (PROTECT) missed its endpoint, and it is an immunosuppressant with real oncology-dose toxicities, so the longevity use stays emerging and off-label.
Everolimus (RAD001) is a semi-synthetic analog of rapamycin — a 'rapalog' — that, like rapamycin, binds FKBP12 and allosterically inhibits mTOR complex 1 (mTORC1), the central growth-signaling hub.
It is FDA-approved as an oncology agent (Afinitor: advanced renal cell carcinoma, hormone-receptor-positive breast cancer, neuroendocrine tumors, and TSC-associated lesions) and as a transplant immunosuppressant (Zortress), and it has the most directly relevant human data of any mTOR inhibitor for the geroscience hypothesis.
The reason everolimus matters to longevity is a small but influential set of randomized trials from the Mannick/Novartis program: in elderly volunteers, low-dose RAD001 enhanced the antibody response to influenza vaccination and reduced the exhaustion marker PD-1 on T cells (Sci Transl Med 2014); a follow-up combining a low dose of everolimus with the catalytic mTOR inhibitor BEZ235 (selective TORC1 inhibition) was associated with fewer infections and up-regulated antiviral gene expression over the following year (Sci Transl Med 2018).
These are the best human signals that mTOR inhibition can partially reverse immunosenescence.
The honest gap is large: there is NO human trial showing everolimus extends lifespan or healthspan, and the program's own larger confirmatory effort — the phase 2b/3 trials of the related mTOR inhibitor RTB101 (resTORbio) — failed, with the phase-3 PROTECT trial missing its primary endpoint of reducing clinically symptomatic respiratory illness in older adults.
So the immune-aging signal is real but unconfirmed at scale. Everolimus is also a genuine immunosuppressant with oncology-dose toxicities: stomatitis (mouth ulcers), non-infectious pneumonitis, infections, hyperglycemia and hyperlipidemia, and impaired wound healing.
Off-label longevity use is unproven, uses far lower/intermittent doses than the approved oncology regimen, and carries the same class risks as rapamycin plus everolimus-specific pneumonitis.
The score reflects a uniquely relevant — but small and unconfirmed — human immune-aging dataset against the absence of any lifespan outcome and real immunosuppressant risk.
Like rapamycin, everolimus binds FKBP12 and allosterically inhibits mTORC1, dampening anabolic/growth signaling — the basis of both its anti-tumor and proposed geroprotective effects.
Low-dose mTOR inhibition lowered exhaustion-marker PD-1 on T cells and enhanced vaccine response in older adults — a proposed mechanism for improved immune function with age.
Suppressed protein synthesis and cell growth underlie both the anti-proliferative oncology effect and the immunosuppression / impaired wound healing.
How Everolimus works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
No validated longevity dose. Geroscience trials used low intermittent dosing (e.g. ~0.5 mg/day or ~5 mg/week of RAD001) — unproven and not an approved regimen. Approved oncology dosing is 10 mg/day (Afinitor) and transplant dosing is trough-titrated (Zortress); both are far higher than any longevity protocol.
Can be taken without food
| Form | Type |
|---|---|
| 💊Oral everolimus tablet | Recommended |
| 💊Rapamycin (sirolimus) — the parent mTOR inhibitor with the deeper animal-lifespan data | Alternative |
Everolimus has the most directly relevant human immune-aging trials; rapamycin has the deeper preclinical lifespan record. Use pharmaceutical product under supervision.
Minimum: 6 weeks
Optimal: 52 weeks
Cycling: Geroscience trials deliberately used low and/or intermittent dosing to inhibit mTORC1 while limiting immunosuppression — but the optimal longevity schedule is unproven. Oncology dosing is continuous and not a longevity model.
Note: Take consistently. Oncology dosing is daily; geroscience trials used low/intermittent dosing. Avoid grapefruit and strong CYP3A4 inhibitors.
Dose-response data unavailable. The current published research for Everolimus does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Randomized trials showed low-dose everolimus improved influenza-vaccine response and a TORC1-selective regimen reduced infections in older adults.
Extends progression-free survival in renal cell carcinoma, HR-positive breast cancer, and neuroendocrine tumors — its approved indication, not a longevity outcome.
An immunosuppressant — raises infection risk; non-infectious pneumonitis and mouth ulcers (stomatitis) are characteristic everolimus toxicities.
Hyperglycemia and hyperlipidemia are common at oncology doses; impaired wound healing around surgery.
Avoid — mTOR inhibition is contraindicated in pregnancy.
Monitor glucose and lipids; mTOR inhibition can worsen both.
Hold around procedures — impaired wound healing and immunosuppression.
Caution — non-infectious pneumonitis is a known everolimus risk; report new respiratory symptoms.
Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, grapefruit) sharply raise everolimus levels; inducers (rifampin) lower them. Dosing must account for this.
Immunosuppression can blunt vaccine response and makes live vaccines inadvisable during continuous dosing.
Tip: Dose-related and often the dose-limiting toxicity; steroid mouthwash and lower/intermittent dosing reduce it.
Tip: Monitor glucose and lipids; more pronounced at oncology doses.
Tip: A characteristic everolimus toxicity — investigate new cough/dyspnea; may require dose reduction or discontinuation.
Tip: Monitor for infection; hold during acute illness or before surgery.
Timing is flexible for Everolimus — consistent daily use matters more than the time of day. Take consistently with or without food (food lowers exposure).
Everolimus should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are stomatitis (mouth ulcers), hyperglycemia / hyperlipidemia, non-infectious pneumonitis. Use caution if any of these apply to you: Active infection; Pregnancy / breastfeeding; Significant immunosuppression or upcoming surgery (wound healing).
A lipid-soluble antioxidant central to mitochondrial energy production, with the strongest trial support for fertility/IVF outcomes and heart failure.
Additive immunosuppression and infection risk (relevant in transplant regimens).
Co-administration with ACE inhibitors increases the risk of angioedema.